Bookmarks

UKCTOCS Longitudinal Women's Cohort (UKLWC)

Population Size

Not reported
Population Size statistic card

Years

2001

Years statistic card

Associated BioSamples

DNA

Plasma

Associated BioSamples statistic card

Geographic coverage

United Kingdom

England

Geographic coverage statistic card

Lead time

Other

Lead time statistic card

Summary

Samples & data for following diseases: Cerebrovascular accident ,Dementia ,Fit and well, Heart disease ,Malignant neoplasm of endometrium of corpus uteri ),Malignant tumour of breast,Malignant colon tumour, and others. Full list in Description…

Documentation

This is the bioresource resulting from the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), one of the world's largest randomised controlled trials. Between 2001-2005 1.2 million women aged 50-74 years were invited from the general population and 202,638 post-menopausal were randomised (2:1:1) to routine care, or annual CA125 blood testing (7-11 rounds) or ultrasound to evaluate the impact of ovarian cancer screening on disease mortality. All participants provided a serum sample at recruitment with 50,262 providing further longitudinal annual samples (median of 9 samples). Women were free of any active malignancy at enrolment (2001-2005). During the follow-up period of >15 years to-date a proportion of those have subsequently developed a number of different diseases. Available comprehensive electronic health record linkage of the cohort's participants (including Hospital Episode Statistics (HES); ONS (Cancer registry, Death Certificates); National Cancer Intelligence Network (NCIN); and Myocardial Ischaemia National Audit Project (MINAP) allows exploiting clinical phenotyping and diseases diagnoses made during routine healthcare in the NHS. Women were also sent postal questionnaires. Secondary studies have to date generated additional data on symptoms, menopause and its management and further details of individual cancers. The biobank contains >540,000 high-quality serum samples (10 x 500μL aliquots in straws), composed of baseline (from >189,000 women) and a unique longitudinal set of >350,000 annual serial samples (median 9) (from approximately 50,200 women). Samples have already been validated for multi-omics analysis with academic and commercial collaborators in nested case/controls sets used for genotyping, proteomics (including SWATH technology), methylation, NMR metabolomics, autoantibody profiling, ELISA-based assays, lipidomics and miRNA. We provide access to collection of samples and data across the following diseases: • Cerebrovascular accident (disorder) • Dementia (disorder) • Fit and well • Heart disease (disorder) • Malignant neoplasm of endometrium of corpus uteri (disorder) • Malignant tumour of breast, Malignant tumour of colon, Malignant tumour of lung, Malignant tumour of ovary • Malignant tumour of pancreas All data is stored in the IG Toolkit-compliant and ISO 27001:2013-certified UCL Data Safe Haven. All samples from the biobank have been collected using a standardised protocol and stored in liquid nitrogen at HTA licensed facilities at UK Biocentre, Oxford, UK.

Dataset type

Health and disease

Dataset sub-type

Not applicable

Keywords

Provenance

Image contrast

Not stated

Biological sample availability

DNA,Plasma,Serum

Details

Publishing frequency

Other

Version

1.0.0

Modified

08/10/2024

Distribution release date

11/05/2018

Citation Requirements

In Progress

Coverage

Start date

01/01/2001

Time lag

Variable

Geographic coverage

United Kingdom, England

Minimum age range

40

Maximum age range

150

Accessibility

Language

en

Controlled vocabulary

LOCAL

Format

In Progress

Data Access Request

Dataset pipeline status

Not available

Access rights

Please contact the publisher using Contact Point details provided

Time to dataset access

Other

Access request cost

Not specified

Access method category

Varies based on project

Data Controller

UCL

Dataset Types: Health and disease


Collection Sources:

end of page